Myelodysplastic syndromes

Peter L. Greenberg, Eyal Attar, Minoo Battiwalla, John M. Bennett, Clara D. Bloomfield, Carlos M. DeCastro, Joachim Deeg, Harry P. Erba, James M. Foran, Guillermo Garcia-Manero, Steven D. Gore, David Head, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Hussain I. Saba, Paul J. Shami, Kathy Spiers, Richard M. StoneMartin S. Tallman, Peter Westervelt

Research output: Contribution to journalReview article

18 Scopus citations

Abstract

These suggested practice guidelines are based on extensive evaluation of reviewed risk-based data and indicate useful current approaches for managing patients with MDS. The FDA recently approved 4 drugs for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic, abnormalities; azacytidine and decitabine for treating higher-risk or nonresponsive MDS patients; and deferasirox for iron chelation of MDS patients with iron overload. However, because a substantial proportion of MDS patient subsets lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines in managing thrombocytopenia in MDS requires fiirther evaluation. In addition, further determination of the effects of these therapeutic interventions on patient QOL is important.97,100,101,109,110 Progress toward improving management of MDS has occurred over the past few years and more advances are anticipated using these guidelines as a framework for coordinating comparative clinical trials.

Original languageEnglish (US)
Pages (from-to)902-925
Number of pages24
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue number9
DOIs
StatePublished - Oct 2008
Externally publishedYes

Keywords

  • Chronic myelomonocytic leukemia
  • Cytopenias
  • Myelodysplastic syndromes
  • NCCN clinical practice guidelines
  • Refractory anemia
  • Treatment

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Myelodysplastic syndromes'. Together they form a unique fingerprint.

  • Cite this

    Greenberg, P. L., Attar, E., Battiwalla, M., Bennett, J. M., Bloomfield, C. D., DeCastro, C. M., Deeg, J., Erba, H. P., Foran, J. M., Garcia-Manero, G., Gore, S. D., Head, D., Maness, L. J., Millenson, M., Nimer, S. D., O'Donnell, M. R., Saba, H. I., Shami, P. J., Spiers, K., ... Westervelt, P. (2008). Myelodysplastic syndromes. JNCCN Journal of the National Comprehensive Cancer Network, 6(9), 902-925. https://doi.org/10.6004/jnccn.2008.0069